在KRAS突变瘤中,YB-1激活级联作为潜在标
Shayan Khozooei1, Soundaram Veerappan1, Mahmoud Toulany2
1Division of Radiobiology and Molecular Environmental Research, Department of Radiation Oncology, University of Tuebingen, Tuebingen, Germany.
概括
Y盒结合蛋白-1 (YB-1) 对癌细胞过程和对化疗放射治疗 (CRT) 的反应至关重要. 向KRAS/YB-1通路可能会改善KRAS突变固体瘤中CRT的结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- Y盒结合蛋白-1 (YB-1) 是一种多功能蛋白质,在各种人类固体瘤中高度表达.
- YB-1 调节关键的细胞过程,包括细胞周期进展,癌症干和DNA损伤信号,所有这些都对化疗辐射疗法 (CRT) 反应至关重要.
- KRAS突变在癌症中很普遍,已知瘤性KRAS介导了对CRT的抗性.
研究的目的:
- 审查KRAS/YB-1信号级联在KRAS突变固体瘤对CRT反应中的意义.
- 探索针对KRAS/YB-1通路的潜在治疗策略,以提高CRT的疗效.
主要方法:
- 文献综述侧重于KRAS,YB-1和CRT反应之间的相互作用.
- 对KRAS下游的激酶,如AKT和p90核糖体S6激酶的当前研究分析,以及它们在YB-1酸化中的作用.
主要成果:
- 在KRAS突变状态和YB-1活动之间存在强烈的相关性.
- 瘤性KRAS信号激活了YB-1酸化的下游激酶,影响了CRT耐药性.
- KRAS/YB-1级联是KRAS突变固体瘤治疗反应的关键决定因素.
结论:
- 该KRAS/YB-1通路在KRAS突变固体瘤对化学辐射疗法的反应中起着关键作用.
- 干扰KRAS/YB-1级联是一种有希望的治疗途径,可以改善这些患者的CRT结果.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The Ras Gene
6.3K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


